FDA Supports Qualified Health Claim for Magnesium and Reduced Hypertension Risk
The strength of the scientific evidence supporting the relationship will be disclosed as “supportive but inconclusive” to avoid misleading consumers.
Hypertension
Long-Term Outcomes of a Workplace-Based Hypertension Management Program
Researchers assessed whether a hypertension management program in a workplace setting was effective for helping individuals with long-term BP control.
Chlorthalidone Safe, Effective for Treating Hypertension in Advanced CKD
In a study of patients with stage 4 chronic kidney disease and poorly controlled blood pressure, chlorthalidone significantly decreased systolic blood pressure compared with placebo.
CaroSpir, a Liquid Form of Spironolactone, Now Available in Unit Dose Cups
The new packaging allows for ease of administration and convenience.
Lower BP Affects CVD Event Risk in Adults With Hypertension and LVH
While health benefits of intensive blood pressure lowering have been observed in people at high risk for CVD, researchers sought to examine its effects in patients with hypertension and LVH.
Lifestyle Changes Lower BP in Patients With Resistant Hypertension
Researchers conducted a randomized clinical trial to assess the effects of lifestyle modifications on resistant hypertension.
AHA Scientific Statement Addresses Weight Loss Strategies for Hypertension Prevention and Treatment
The American Heart Association released a scientific statement reviewing weight loss strategies for the prevention and treatment of hypertension.
Clinical Challenge: An Underdiagnosed Cause of Resistant Hypertension
Once thought to be rare, the prevalence of primary aldosteronism is estimated to be 5% to 17%, although the condition remains underdiagnosed.
ACE Inhibitors vs ARBs for First-Line Hypertension Treatment
Currently, ACE inhibitors and ARBs are both recommended as first-line therapies for the treatment of hypertension according to US and European guidelines.
HOPE-3 Trial: Lasting Effect of Rosuvastatin Prevents Major Cardiovascular Events
HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
- Loading...
Loading...
Loading... 
Loading...